Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A pilot study found that most breast cancer patients can successfully self-administer leuprolide injections at home, with strong satisfaction among both patients and oncologists. But insurance hurdles and out-of-pocket costs blocked many from even trying — nearly half of interested participants couldn't proceed due to lack of coverage or high copayments.
A new pilot study published in JAMA Network Open shows that home-based self-injection of GnRHa therapy — specifically leuprolide — is both feasible and well-received by breast cancer patients. Of the 24 women who participated, 95.8% successfully completed at least one home injection, and 75% kept it up after the study ended. Patients praised the model for saving time, improving scheduling flexibility, and reducing disruption to daily life.
Oncologists were on board too, giving the self-administration model a net promoter score of 61 — a strong endorsement. The study also offered telemedicine nursing support for the first two home injections, helping ease the transition even for patients with no prior injection experience.
The catch? Insurance. Nearly 35% of interested patients couldn't participate due to lack of coverage approval, and another group dropped out after facing copayments as high as $2,000 when leuprolide shifted from a medical to a pharmacy benefit.
By the Numbers:
Why it matters: Home injection models could meaningfully cut treatment burden for breast cancer patients — but only if insurance and cost-sharing policies catch up. Without policy reform and better financial assistance programs, this promising approach risks remaining out of reach for many.
